{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T15:41:38Z","timestamp":1772638898887,"version":"3.50.1"},"reference-count":0,"publisher":"JLE","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,1]]},"DOI":"10.1684\/ndt.2025.160","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T12:00:11Z","timestamp":1767096011000},"page":"587-595","source":"Crossref","is-referenced-by-count":0,"title":["Le ciblage du compl\u00e9ment dans le syndrome h\u00e9molytique et ur\u00e9mique atypique : d\u00e9veloppement et place actuelle de l\u2019\u00e9culizumab et du ravulizumab"],"prefix":"10.1684","volume":"21","author":[{"given":"Nicolas","family":"Maillard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fran\u00e7ois","family":"Provot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"18929","container-title":["N\u00e9phrologie & Th\u00e9rapeutique"],"original-title":[],"deposited":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T10:00:18Z","timestamp":1772618418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jle.com\/10.1684\/ndt.2025.160?ref=doi"}},"subtitle":[""],"short-title":[],"issued":{"date-parts":[[2025,12,1]]},"references-count":0,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,12,1]]}},"URL":"https:\/\/doi.org\/10.1684\/ndt.2025.160","relation":{},"ISSN":["1769-7255"],"issn-type":[{"value":"1769-7255","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12,1]]}}}